Head-to-head · WeighScore
FlyteHealth vs NovoCare Pharmacy
The verdict
FlyteHealth takes it — 58.6/100 to 55.2/100.
FlyteHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FlyteHealth is an obesity-medicine telehealth platform distributed mainly through employers, payers, and health plans, with care led by board-certified obesity-medicine physicians plus nurse practitioners,…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | FlyteHealth | NovoCare Pharmacy |
|---|---|---|
| WeighScore | 58.6/100 | 55.2/100 |
| Grade | C | C |
| Scorecard rank | #364 | #442 |
| Semaglutide | Not disclosed | $349/mo (2.4 mg dose, brand-name) |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Yes |
Graded #364 · C
Strengths
- Care led by board-certified obesity-medicine physicians
- Multidisciplinary team with NPs, dietitians, and care coordinators
- Published outcomes of about 13 to 16 percent weight loss over 12 months
- High GLP-1 medication adherence (around 86 percent in reported data)
- Comprehensive cardiometabolic care beyond GLP-1 alone
Where it loses points
- Distributed primarily via employers, payers, and health plans, not direct cash-pay
- Access is largely gated behind employer or plan sponsorship
- GLP-1 is prescribed only when appropriate, not guaranteed
- Self-pay pricing is not publicly listed (contact required)
- Less suited to consumers wanting fast direct-to-door GLP-1
Graded #442 · C
Strengths
- First-party Novo Nordisk pharmacy — the most authoritative branded Wegovy channel
- $199/mo intro pricing on Wegovy 0.25/0.5 mg starter doses (through 6/30/2026), the lowest brand self-pay price
- $349/mo standard self-pay is well below the ~$1,300/mo retail list price
- Ships to all 50 states with no telehealth-platform middleman fees
- Cold-chain logistics handled directly by Novo Nordisk
Where it loses points
- Wegovy only — no Ozempic, no tirzepatide, no compounded GLP-1
- Requires an existing Wegovy prescription — no prescribing clinicians or telehealth intake
- No clinical support included — your own prescriber handles titration and side effects
- Manufacturer-set pricing can change at any time
- $199 pen intro covers only the first 2 fills for new patients (through 6/30/2026); maintenance doses are $349/mo ($399 HD)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.